title: In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease.
abstract: AG7088 is a potent, irreversible inhibitor of human rhinovirus (HRV) 3C protease (inactivation rate constant (k(obs)/[I]) = 1,470,000 +/- 440,000 M(-1) s(-1) for HRV 14) that was discovered by protein structure-based drug design methodologies. In H1-HeLa and MRC-5 cell protection assays, AG7088 inhibited the replication of all HRV serotypes (48 of 48) tested with a mean 50% effective concentration (EC(50)) of 0.023 microM (range, 0.003 to 0.081 microM) and a mean EC(90) of 0.082 microM (range, 0.018 to 0.261 microM) as well as that of related picornaviruses including coxsackieviruses A21 and B3, enterovirus 70, and echovirus 11. No significant reductions in the antiviral activity of AG7088 were observed when assays were performed in the presence of alpha(1)-acid glycoprotein or mucin, proteins present in nasal secretions. The 50% cytotoxic concentration of AG7088 was >1,000 microM, yielding a therapeutic index of >12,346 to >333,333. In a single-cycle, time-of-addition assay, AG7088 demonstrated antiviral activity when added up to 6 h after infection. In contrast, a compound targeting viral attachment and/or uncoating was effective only when added at the initiation of virus infection. Direct inhibition of 3C proteolytic activity in infected cells treated with AG7088 was demonstrated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis of radiolabeled proteins, which showed a dose-dependent accumulation of viral precursor polyproteins and reduction of processed protein products. The broad spectrum of antiviral activity of AG7088, combined with its efficacy even when added late in the virus life cycle, highlights the advantages of 3C protease as a target and suggests that AG7088 will be a promising clinical candidate.
authors.affiliation: Agouron Pharmaceuticals, Inc., San Diego, California 92121, USA. amy.patick@agouron.com
authors.forename: A K
authors.initials: AK
authors.lastname: Patick
authors.forename: S L
authors.initials: SL
authors.lastname: Binford
authors.forename: M A
authors.initials: MA
authors.lastname: Brothers
authors.forename: R L
authors.initials: RL
authors.lastname: Jackson
authors.forename: C E
authors.initials: CE
authors.lastname: Ford
authors.forename: M D
authors.initials: MD
authors.lastname: Diem
authors.forename: F
authors.initials: F
authors.lastname: Maldonado
authors.forename: P S
authors.initials: PS
authors.lastname: Dragovich
authors.forename: R
authors.initials: R
authors.lastname: Zhou
authors.forename: T J
authors.initials: TJ
authors.lastname: Prins
authors.forename: S A
authors.initials: SA
authors.lastname: Fuhrman
authors.forename: J W
authors.initials: JW
authors.lastname: Meador
authors.forename: L S
authors.initials: LS
authors.lastname: Zalman
authors.forename: D A
authors.initials: DA
authors.lastname: Matthews
authors.forename: S T
authors.initials: ST
authors.lastname: Worland
mesh_terms: D000086042:3C Viral Proteases; D000998:Antiviral Agents / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D003546:Cysteine Endopeptidases / Q000187:drug effects* / Q000378:metabolism; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology; D006367:HeLa Cells; D006801:Humans; D007555:Isoxazoles / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D010649:Phenylalanine / Q000031:analogs & derivatives; D011506:Proteins / Q000494:pharmacology; D011760:Pyrrolidinones / Q000494:pharmacology*; D012229:Rhinovirus / Q000187:drug effects* / Q000502:physiology; D012703:Serotyping; D014633:Valine / Q000031:analogs & derivatives; D014764:Viral Proteins
chemical_list: D000998:Antiviral Agents; D015853:Cysteine Proteinase Inhibitors; D007555:Isoxazoles; D011506:Proteins; D011760:Pyrrolidinones; D014764:Viral Proteins; D010649:Phenylalanine; D003546:Cysteine Endopeptidases; D000086042:3C Viral Proteases; D014633:Valine; C118874:rupintrivir